The present invention relates to a composition for diagnosing lung cancer including a preparation capable of measuring expression levels of lung cancer-specific biomarkers SAA, OPN, and CEA at the same time, a kit for diagnosing lung cancer including the same, and a method of diagnosing lung cancer using the composition. The composition for diagnosing lung cancer has effects such as enhanced sensitivity and specificity as compared to conventional biomarkers, thereby exhibiting high diagnostic efficiency.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The disclosure provides methods and compositions, e.g., kits and microarray, for assessing the immune response in a murine tumor model based on the expression of a gene panel that characterizes tumor immune interactions.

This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

Systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor are disclosed. The methods use sequence information of the neoepitope.

Disclosed herein are methods for analyzing predictors including quantitative values of biomarkers (e.g., protein biomarkers) for predicting risk of cancer in a human subject. Further disclosed herein are kits for measuring quantitative values of the markers as well as computer systems and software embodiments for predicting risk of cancer in a human subject based on the quantitative values of the biomarkers (e.g., protein biomarkers).

The present disclosure is directed to a method that involves selecting a subject having a primary tumor and obtaining, from the selected subject, a sample containing exosomes derived from primary tumor cells. The exosomes are isolated from the sample and expression levels of cell migration-inducing and hyaluronan-binding protein (CEMIP) are detected in the isolated exosomes.

The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

Personalized mRNA cancer vaccines, as well as methods for their optimization and for their use in subjects are provided. In some embodiments, personalized mRNA cancer vaccines and their uses are provided for subjects having particular characteristics, e.g., the presence of certain biomarkers.